Skip to content
OpenCapital
Get started

Theravance Biopharma TBPH Cash & Equivalents

Cash & Equivalents at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$95.6M+156%
LQD
Liquidia CorporationLQDA
$222.79M+31.2%
Royalty Pharma logo
Royalty PharmaRPRX
$586.4M-46.1%
United Therapeutics logo
United TherapeuticsUTHR
$1.28B-32.6%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$41.01M-38.3%
Precigen logo
PrecigenPGEN
$7.48M+23.5%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×—
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%—
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's cash & equivalents?
Theravance Biopharma (TBPH) reported cash & equivalents of $288.1M in Q1 2026.
How has Theravance Biopharma's cash & equivalents changed year-over-year?
Theravance Biopharma's cash & equivalents increased by 160.5% year-over-year, from $110.61M to $288.1M.
What is the long-term trend for Theravance Biopharma's cash & equivalents?
Over 5 years (2020 to 2025), Theravance Biopharma's cash & equivalents has grown at a 15.5% compound annual growth rate (CAGR), from $81.47M to $167.81M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.